Fenofibrate 200mg

DRUG4 trials

Sponsors

Zhejiang University, AstraZeneca, Alaa Hassan ElBaz, Xijing Hospital of Digestive Diseases

Conditions

Diabetic RetinopathyHyperlipoproteinemiaHypertriglyceridemiaNon-alcoholic Fatty Liver Disease (NAFLDPrimary Biliary Cholangitis

Phase 2

A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.

CompletedNCT02354976

AstraZenecaHypertriglyceridemia, Non-alcoholic Fatty Liver Disease (NAFLD

Start: 2015-09-01End: 2016-05-26Updated: 2018-09-25

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

RecruitingNCT05749822

Xijing Hospital of Digestive DiseasesPrimary Biliary Cholangitis

Start: 2023-02-17End: 2027-12-31Target: 104Updated: 2026-01-08

Phase 3

Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia

CompletedNCT01878227

Zhejiang UniversityHyperlipoproteinemia

Start: 2010-07-31End: 2011-06-30Updated: 2013-06-14

Phase 4

Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients

Alaa Hassan ElBazDiabetic Retinopathy

Start: 2020-02-29End: 2020-08-31Target: 80Updated: 2020-01-18

Related Papers

Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay

Molecular & Cellular Proteomics2019-10-0721 citations

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.

2018-08-1087 citations